Notable exceptions whereby co-inhibition of one pathway yielded synergistic efficacy despite one agent being devoid of monotherapy activity include the combination of fluorouracil with leucovorin across diverse malignancies, as well as the combination of EGFR and BRAF inhibition for BRAF-mutated colorectal cancer [209]. The gene discussed is BRAF; the disease is colorectal cancer.